Evidence mapPaperPMID 41350836Full record

ArticleBiological procedures online2025

(-)-Guaiol Downregulates M2 Tumor-Associated Macrophage Polarization Through PPAR-γ Signaling to Suppress Lung Cancer.

Zhen-Yu Zhao, Jian-Chun Wu, Ying-Bin Luo, Yu-Li Wang, Xi Wang, Jian-Hui Tian, Bo Zhang, Yan Li

Abstract read
In one paragraph

Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen-Yu Zhao *Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.ORCID http://orcid.org/0009-0009-5812-2063
Jian-Chun Wu *Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Ying-Bin LuoClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Yu-Li WangClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Xi WangClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Jian-Hui TianClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Bo ZhangClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China. bob229@163.com.
Yan LiClinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China. yan.xiaotian@shutcm.edu.cn.

Funding

Shanghai famous old Chinese medicine academic experience research studio construction project No. SHGZS-202210Shanghai Three-year Action Plan to Further Accelerate the Development of Traditional Chinese Medicine Inheritance and Innovation (2021-2023) No.ZY(2021-2023)-0211The National Natural Science Foundation of China No. 82174183The National Natural Science Foundation of China No. 82204842the three-year clinical action Plan of Shanghai Shenkang Hospital Development Center No. SHDC2020CR4052the YangFan project from the Science and Technology Commission of Shanghai Municipality No. 22YF1445400This study was supported by Shanghai University of Traditional Chinese Medicine Science and Technology Development Project 24KFL090
6 · The paper itself

Abstract

backgroundM2 macrophages play a pivotal role in promoting the growth and metastasis of lung cancer cells. Inhibiting M2 macrophage polarization represents an effective immunotherapeutic approach against tumors. Although (-)-Guaiol has been shown to exert potent inhibitory effects on M2 macrophage polarization, its underlying molecular mechanism remains unclear.

objectiveThis study aimed to elucidate the effects of (-)-Guaiol on M2 macrophage polarization and to explore the potential molecular mechanisms involved.

methodsBone marrow-derived macrophages (BMDMs) from mice were polarized toward the M2 phenotype using IL-4 and M-CSF. Both ex vivo and in vivo experiments were performed to determine whether (-)-Guaiol suppresses M2 macrophage polarization through the PPAR-γ-related signaling pathway. PPAR-γ agonists and inhibitors were applied to confirm the involvement of PPAR-γ in the effects of (-)-Guaiol. A co-culture system of M2 macrophages and Lewis lung carcinoma (LLC) cells was established. Wound healing, Transwell invasion, and plate cloning experiments were performed to determine the effects of (-)-Guaiol on the metastasis and development of lung cancer cells.

results(-)-Guaiol markedly downregulated the expression of CD206, a characteristic surface marker of M2-polarized macrophages. It also significantly inhibited the proliferation, invasion, and metastatic potential of LLC cells co-cultured with M2 macrophages. Animal experiments revealed that (-)-Guaiol treatment significantly decreased the tumor volume and weight, as well as CD206 expression. Moreover, integrated in vitro and in vivo analyses revealed that (-)-Guaiol inhibited M2 macrophage polarization primarily by suppressing the PPAR-γ signaling pathway.

conclusionThese findings demonstrate that (-)-Guaiol inhibits M2 macrophage differentiation via targeted suppression of the PPAR-γ-related signaling pathway, thereby reducing the proliferation, migration, and invasion of lung cancer cells.

Indexed as

CD36CPT1(-)-GuaiolLewis lung cancerPPAR-γ

Identifiers

PMID41350836
PMCPMC12801675

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.